TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Dec 09, 2022
Monday they hold an analysts meeting to discuss their drug pipeline. Their biggest problem is that the street thinks there isn't much more to this company than its Covid franchise. Untrue! They've made enough acquisitions and invested in their pipeline to keep making new drugs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$51.72

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 23, 2022
Sell PFE to buy MRK? Likes and owns them both. MRK is more in the immuno oncology and cancer space, whereas PFE is more diversified. Defensive and growth characteristics. MRK hit a new high today. PFE hasn't done as well, but has performed over the last 2 years. Own both for different reasons. May want to trim in early part of next cycle. Yield is 3.3%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$48.78

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 12, 2022
It has always been part of their health care portfolio. It is losing some lustre and interest created by Covid but is still a good health care company with a good dividend. He likes others as well, maybe a bit better.
Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$47.76

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Sep 08, 2022
When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.4%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$46.79

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 01, 2022
PFE vs. JNJ Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
Photo of Jason MannJason Mann
Owned
Unlock Rating
$46.48

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 10, 2022
Always a wall of worry around drug pricing, but rarely does it have a large impact. He sold this name after record revenues from vaccine news. He likes AZN, which is getting approval after approval. Another one is LLY, focusing on its diabetes and weight loss drug.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$49.52

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 15, 2022
Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.
Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital Advisors
Owned
Unlock Rating
$51.75

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 21, 2022
The entire drug sector hasn't been investable since the 1990s, because governments control drug prices and patent expiries. Pfizer is struggling to replace drugs coming off patent, like their cholesterol drug. It's really tough. It's a defensive sector, so the drug companies will hold up better and offer dividend growth.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$48.11

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Jun 14, 2022
(A Top Pick Apr 19/22, Down 3.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has triggered its stop at $48. To remain disciplined we recommend covering the position at this time.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$47.70

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 08, 2022
Results highly influenced by Covid vaccine. Earnings might be stagnant going forward. His choice is MRK, reasonable and sustainable multiple of 12x and very good dividend. MRK's major drug is patent-protected until at least 2026, plus great drugs in pipeline.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$53.65

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

May 26, 2022
(A Top Pick Apr 19/22, Up 9.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $42) to $48.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$54.09

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 12, 2022
Diversified business, gold standard. PFE is making acquisitions, building out the pipeline from Covid cashflow wins. Good mRNA franchise, benefits of diversity, plus management team executing on pipeline of acquisitions.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$49.01

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 10, 2022
(A Top Pick May 28/20, Up 45%) A defensive. Back then, they were working on the vaccine and luckily theirs was the most effective. He trimmed at $55, but still likes and holds it. The company has in the past struggled to build a pipeline of drugs. This morning they announced they will buy a company that treats migraines. They're spending $11 billion on their pipeline, which is promising. They earned $25 billion revenues in vaccines in 2021. Pays a great dividend. Remains a core holding.
Photo of Robert LauzonRobert LauzonUnlock Rating
$49.16

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Apr 29, 2022
They report Tuesday. They've made a lot of money during the pandemic. He hopes they buy another drug company to make up for looming patent explorations in the coming years. Shares were crushed today. Good yield and trades at 6x earnings, though.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$49.07

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Pfizer Inc(PFE)

Apr 19, 2022
Stockchase Research Editor: Michael O'Reilly PFE has a long pipeline of new drugs focusing on oncology, rare diseases and vaccines, generating over $50 billion in annual sales. It trades at 13x earnings compared to peers at 20x. Latest reported earnings beat expectations by 27% and supports a ROE over 34%. Its dividend is backed by a payout ratio under 40% of cashflow. It is managing its cash reserves conservatively, maintaining a good war chest, while still retiring debt. We would recommend a stop loss at $42.00, looking to achieve $60.50 -- upside potential of 19%. Yield 3.0% (Analysts’ price target is $60.47)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$49.58

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 136 to 150 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like